Novo Nordisk settles Minnesota insulin pricing case

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...